Aardvark Therapeutics, Inc. Common Stock

AARDNASDAQ • USD
ThemeBiotech - Drug Development›Metabolic & Cardiometabolic
7.30 USD
↘ 0.22 (2.93%)AT CLOSE (11:59 AM EDT)
7.33
↗ 0.03 (0.41%)
POST MARKET (AS OF 07:53 PM EDT)
Post Market
AS OF 07:53 PM EDT
7.33
↗ 0.03 (0.41%)
🔴Market: CLOSED

Aardvark Therapeutics, Inc. Common Stock (AARD) trades at $7.33 per share. The technical outlook is "Buy" and the fundamental picture shows "Neutral". Notable factors include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. The stock looks compelling on valuation, with multiples below sector averages across P/E, P/B, and EV/EBITDA.

Technical & fundamental data as of Aug 6, 2026.

Open?$7.56
High?$7.56
Low?$7.15
Prev. Close?$7.52
Volume?63.1K
Avg. Volume?387.7K
VWAP?$7.31
Rel. Volume?0.16x
Bid / Ask
Bid?$5.90 × 2.7K
Ask?$8.50 × 500
Spread?$2.60
Midpoint?$7.20
Valuation & Ratios
Market Cap?164.6M
Shares Out?21.9M
Float?12.2M
Float %?56.0%
P/E Ratio?N/A
P/B Ratio?1.89
EPS?-$3.19
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
Themes
Biotech - Drug Development›Metabolic & CardiometabolicBiotech - Drug Development›Rare Disease Therapeutics
Employees
40
Market Cap
164.6M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.aardvarktherapeutics.com
Listed
2025-02-13
Address
4370 LA JOLLA VILLAGE DRIVE
SAN DIEGO, CA 92122
Phone: (858) 225-7696
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+1/3)
Medium-Term (Wave)?▲ Bullish(+2/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
98
Momentum?
23
Short Sent.?
71
Piotroski F-Score?0/9Weak
Altman Z-Score?5.05Safe
Confidence?36%Very Low
Full Fundamental Analysis →
Short InterestElevated
Short % of Float?5.34%Elevated
Short Interest?651.8K
Days to Cover?1.0
Free Float12.2M
Avg Daily Volume675.7K
Settlement Date2026-07-15
Financial Health
Current Ratio?8.06Strong
Quick Ratio?8.06Strong
Cash Ratio?5.38Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
77
1.89CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-1.4CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-80.3%WEAK▾
ROA?
S&P
3
-70.9%WEAK▾
Cash Flow & Enterprise
FCF?$-61748000
Enterprise Value?$102.1M
Fundamentals ratios updated end of day
MarketsMoversWatchlist